Sign in
Taking people in United StatesNo phase

Eating avocado instead of refined carbohydrate foods, and its effect on inflammation

Tests daily avocado in place of sugary foods in adults with inflammation and excess weight.

Key facts

Who runs it
Midwest Center for Metabolic and Cardiovascular Research
Where
Chicago and Las Vegas, United StatesSee the 2 sites
Trial code
Registry title
Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.
Status
Recruiting
People taking part
38 people, planned
Started
2 Jul 2026
Expected to end
Feb 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Avocado
  • Control
Record updated
27 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 21 to 74 with raised inflammation (hs-CRP), extra belly fat and overweight or obesity. It tests replacing foods high in refined carbohydrates with avocado.

Age
21 to 74 years
Sex
Women and men
Disease stage
Baseline hs-CRP of 2 to less than 10 mg/L; waist 35 inches or more in women and 40 inches or more in men; body mass index 25.0 to 39.9 kg/m2.
Earlier treatment
Must not have recently used certain medicines, such as diabetes drugs, weight-loss drugs, beta-blockers or anti-inflammatory prescription medicines, within 4 weeks before the first visit. Must not have had bariatric surgery.
Biomarker or test result
hs-CRP of 2 to less than 10 mg/L.

Main reasons for not taking part

  • Known metabolic disease such as type 1 or type 2 diabetes
  • Clinical atherosclerotic disease
  • Cancer in the past 2 years (except non-melanoma skin cancer or carcinoma in situ of the cervix)
  • Pregnant, planning pregnancy or breastfeeding
  • Allergy or intolerance to the study foods

The registry criteria, word for word

Show all 44 criteriaShow less

Who can take part

  • Male or female 21 - 74 years of age, inclusive
  • Baseline hs-CRP ≥2 to <10 mg/L
  • Central adiposity (waist circumference ≥35 inches in women and ≥40 inches in men)
  • Body mass index 25.0 to 39.9 kg/m2
  • Normally active and judged by the Investigator to be in generally good health, based on medical history and screening measurements
  • Willing to consume daily study foods during each diet condition
  • Willing to maintain his/her regular physical activity pattern throughout the study period
  • Willing to follow test day instructions (refrain from consumption of alcoholic beverages and participation in vigorous physical activity for 24 hours and tobacco and caffeine for 1 hour prior to each test visit)
  • No plans to change smoking, vaping, or other nicotine use habits during the study period; and
  • Premenopausal women that are not using hormonal contraceptives must have a history of regular menstrual cycles (21-35 days per cycle) for at least 3 months prior to visit 1
  • Understands the study procedures and signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator and is willing to complete study procedures

Who cannot take part

  • Positive urine test for illicit drugs at visit 1
  • Unstable use (defined as initiation or change in dose) of anti-hypertensive medication within 4 weeks of visit 1
  • Unstable use (defined as initiation or change in dose) of thyroid hormone replacement medication within 12 weeks of visit 1
  • Use of lipid-altering drugs other than statins including, but not limited to bile acid sequestrants, cholesterol absorption inhibitors, or fibrates within 4 weeks of visit 1
  • Use of any prescription medication with known effects on inflammation (e.g., colchicine, systemic corticosteroids) within 4 weeks of visit 1
  • Frequent use (≥4 doses/week) of non-steroidal anti-inflammatory drugs (NSAID) within 2 weeks of visit 2
  • Use of weight-loss drugs (including over-the-counter medications and/or supplements) or participation in a structured weight loss program within 4 weeks prior to visit 1
  • Recent weight change of ±4.5 kg (~10 lbs.) within 3 months prior to visit 1
  • Has signs and symptoms of an active infection of clinical significance or has taken antibiotics within 5 days prior to any visit (washout is permitted by re-scheduling of the clinic visit)
  • Exposed to any non-registered drug product within 4 weeks of visit 1
  • Use of hemp/marijuana products within 12 months of visit 1. Occasional use (e.g., once or twice a month) within 12 months of visit 1 is allowed but requires at least a 14-day washout prior to visit 2 and the participant must be willing to refrain from use during the study
  • Current or recent history (past 12 months of screening) or strong potential for illicit drug or alcohol abuse. Alcohol abuse will be defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor); and
  • Known metabolic disease (e.g., type 1 or type 2 diabetes, metabolic dysfunction-associated steatohepatitis, etc.)
  • Clinical atherosclerotic disease
  • History or presence of clinically significant gastrointestinal, endocrine, renal, hepatic, hematologic, immunologic, dermatologic, pulmonary, pancreatic, neurologic, psychiatric, inflammatory or biliary disorder that, in the opinion of the Investigator, could interfere with the interpretation of the study results
  • History of cancer in the prior 2 years, except for non- melanoma skin cancer or carcinoma in situ of the cervix
  • Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥100 mm Hg) at screening
  • History of bariatric surgery or plans to have any surgery during the study
  • History of any major trauma or major surgical event within 2 months of visit 1
  • History of an eating disorder (e.g., anorexia, bulimia nervosa, or binge eating) either diagnosed by a health professional or self-reported
  • Known allergy, sensitivity, or intolerance to any components of the study foods
  • Condition the Investigator believes would interfere with his or her ability to provide informed consent or comply with the study protocol, or which might confound the interpretation of the study results or put the person at undue risk
  • Laboratory test result(s) of clinical significance based on the judgment of the Principal Investigator or qualified designee, including fasting glucose ≥126 mg/dL
  • Use of diabetes medications including glucagon-like peptide-1 (GLP-1) receptor agonists, GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, alpha-glucosidase inhibitors, biguanides and biguanide combinations, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides and sulfonylureas and combination sulfonylureas within 4 weeks of visit 1
  • Calculated energy needs of <1800 kcal/d per the Mifflin-St. Jeor Equation, with an adjustment for energy expended in physical activity
  • Use of beta-adrenergic blockers and/or high-dose (>25 mg/d) thiazide diuretics within 4 weeks of visit 1
  • Unstable use (defined as initiation or change in dose, agent, or regimen) of statins within 4 weeks of visit 1
  • Unstable use (initiation or change in dose) within 4 weeks of visit 1 of sex hormones. Multiphasic hormonal contraceptives in which the amount of sex hormone in the active pill varies by week (i.e., biphasic, triphasic, quadriphasic) are considered unstable doses of sex hormones and are exclusionary
  • Use of herbs or dietary supplements that may affect lipid metabolism, including but not limited to omega-3 fatty acid supplements with >500 mg of eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA), niacin (or its analogs) at doses >200 mg/d, sterol/stanol products, dietary fiber supplements, red rice yeast supplements, garlic supplements, and soy isoflavone supplements within 2 weeks of visit 2
  • Use of herbs and dietary supplements that may affect carbohydrate metabolism, including chromium picolinate, ginseng, cinnamon (as a supplement) and starch blockers within 2 weeks of visit 2
  • Extreme dietary habits (e.g., vegan, very low carbohydrate)
  • Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period
  • Currently participating in another research study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 21 and 74 years old?

Where in United States

  • Illinois Institute of TechnologyChicago, United StatesContact: Chelsea PreissTaking people
  • University of Nevada Las VegasLas Vegas, United StatesContact: Neda AkhavanNot yet recruiting

About the trial

What the trial wants to find out

The objective of this trial is to assess the effects of replacing foods high in refined carbohydrates, particularly added sugars, with avocado (isocaloric substitution) on biomarkers of inflammation and insulin sensitivity in adults with elevated hs-CRP and central adiposity. Eligible participants will complete two 4-week interventions (1 avocado/d and control) separated by a 2-week washout phase. Participants will complete a total of 7 clinic visits including one screening visit (visit 1, -7 days), one baseline visit (visit 2, day 0), two visits during each 4-week diet condition (visit 3 \& 6 on day 21 and visits 4 \& 7 on day 28), and one visit at the conclusion of the washout phase/start of the second condition (visit 5, day 0).

The 2 groups in the trial

  • Avocado GroupTreatment being tested

    1 avocado/day provided by 3 servings study products per day (muffins and pudding)

    Treatment: Avocado

  • Control GroupOther group

    3 study products per day will be provided with energy from avocado will be replaced with refined carbohydrate, especially added sugars

    Treatment: Control

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of Avocado Consumption on Inflammation and Insulin Sensitivity in Adults With Elevated High Sensitivity-C-reactive Protein (Hs-CRP): A Randomized, Controlled Crossover Trial
Plain-language title
Eating avocado instead of refined carbohydrate foods, and its effect on inflammationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07566325, who can take part
Record updated
27 August 2026